Header Logo

Connection

CHRISTIE BALLANTYNE to Anticholesteremic Agents

Back to Details
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Anticholesteremic Agents.
CHRISTIE BALLANTYNE
Connection Strength
16.828
Anticholesteremic Agents
  1. Inclisiran: Where Are We on Safety, Efficacy, and Clinical Effectiveness of?siRNA Therapies for Prevention? J Am Coll Cardiol. 2023 12 12; 82(24):2262-2264.
    View in: PubMed
    Score: 0.703
  2. The 2022 American College of Cardiology Expert Consensus on the Role of Nonstatin Therapies: An Expert-Guided Tour. Tex Heart Inst J. 2023 11 17; 50(6).
    View in: PubMed
    Score: 0.699
  3. Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials. Atherosclerosis. 2023 08; 378:117182.
    View in: PubMed
    Score: 0.681
  4. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023 Jul-Aug; 17(4):491-503.
    View in: PubMed
    Score: 0.678
  5. Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid. J Am Heart Assoc. 2022 08 02; 11(15):e024531.
    View in: PubMed
    Score: 0.640
  6. Lowering LDL cholesterol in clinical practice: time for change? Lancet. 2022 07 30; 400(10349):341-343.
    View in: PubMed
    Score: 0.638
  7. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. J Clin Lipidol. 2022 May-Jun; 16(3):286-297.
    View in: PubMed
    Score: 0.623
  8. Management of hyperlipidaemia among statin-intolerant patients after acute coronary syndrome: where do we stand in 2020? Eur J Prev Cardiol. 2021 03 23; 28(1):30-32.
    View in: PubMed
    Score: 0.582
  9. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020 04; 27(6):593-603.
    View in: PubMed
    Score: 0.519
  10. Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
    View in: PubMed
    Score: 0.500
  11. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2019 01; 280:109-117.
    View in: PubMed
    Score: 0.494
  12. Dyslipidaemia: PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia. Nat Rev Cardiol. 2017 07; 14(7):385-386.
    View in: PubMed
    Score: 0.445
  13. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. Am J Cardiol. 2017 Feb 01; 119(3):388-396.
    View in: PubMed
    Score: 0.429
  14. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. Curr Atheroscler Rep. 2016 10; 18(10):61.
    View in: PubMed
    Score: 0.427
  15. Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. Am J Med. 2015 Nov; 128(11):1253-6.
    View in: PubMed
    Score: 0.390
  16. Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
    View in: PubMed
    Score: 0.198
  17. Simulation model to estimate pretreatment (baseline) low-density lipoprotein cholesterol levels in people living with homozygous familial hypercholesterolemia. J Clin Lipidol. 2025 Sep-Oct; 19(5):1457-1462.
    View in: PubMed
    Score: 0.197
  18. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005 Aug 15; 96(4):556-63.
    View in: PubMed
    Score: 0.197
  19. Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics. Am Heart J. 2025 Dec; 290:325-338.
    View in: PubMed
    Score: 0.196
  20. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025 Jul 03; 393(1):51-61.
    View in: PubMed
    Score: 0.194
  21. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J. 2005 Mar; 149(3):464-73.
    View in: PubMed
    Score: 0.191
  22. Inadequate Intensification of LDL-cholesterol lowering therapy after coronary revascularization: Insights from the GOULD registry. Int J Cardiol. 2025 Feb 15; 421:132916.
    View in: PubMed
    Score: 0.189
  23. Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial. Clin Ther. 2004 Nov; 26(11):1855-64.
    View in: PubMed
    Score: 0.187
  24. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol. 2004 Sep 15; 94(6):795-7.
    View in: PubMed
    Score: 0.185
  25. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract. 2004 Jul; 58(7):653-8.
    View in: PubMed
    Score: 0.183
  26. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004 Jun 15; 93(12):1487-94.
    View in: PubMed
    Score: 0.182
  27. Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
    View in: PubMed
    Score: 0.181
  28. Oral PCSK9 Inhibitors. Curr Atheroscler Rep. 2024 05; 26(5):147-152.
    View in: PubMed
    Score: 0.179
  29. Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry. J Am Heart Assoc. 2023 05 02; 12(9):e029175.
    View in: PubMed
    Score: 0.168
  30. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003 May 20; 107(19):2409-15.
    View in: PubMed
    Score: 0.168
  31. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol. 2003 Mar 06; 91(5A):25C-27C; discussion 28C.
    View in: PubMed
    Score: 0.167
  32. Intensity of Lipid-Lowering Therapy Among Patients With Polyvascular Disease. JAMA Netw Open. 2023 03 01; 6(3):e234709.
    View in: PubMed
    Score: 0.166
  33. Combination therapy for combined dyslipidemia. Am J Cardiol. 2002 Nov 20; 90(10B):21K-29K.
    View in: PubMed
    Score: 0.163
  34. Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD). Clin Cardiol. 2022 Dec; 45(12):1303-1310.
    View in: PubMed
    Score: 0.161
  35. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 10 04; 80(14):1366-1418.
    View in: PubMed
    Score: 0.161
  36. PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance. Vasc Health Risk Manag. 2022; 18:555-566.
    View in: PubMed
    Score: 0.159
  37. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001 Dec 18; 104(25):3046-51.
    View in: PubMed
    Score: 0.153
  38. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol. 2001 Aug 01; 88(3):265-9.
    View in: PubMed
    Score: 0.149
  39. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin Ther. 2001 Feb; 23(2):177-92.
    View in: PubMed
    Score: 0.144
  40. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol. 2000 Nov 01; 36(5):1572-8.
    View in: PubMed
    Score: 0.142
  41. Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. Am J Cardiol. 2000 Oct 01; 86(7):759-63.
    View in: PubMed
    Score: 0.141
  42. Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018?AHA/ACC Cholesterol Guidelines. J Am Coll Cardiol. 2019 08 06; 74(5):712-714.
    View in: PubMed
    Score: 0.130
  43. Reducing atherothrombotic events in high-risk patients: recent data on therapy with statins and fatty acids. Curr Atheroscler Rep. 1999 Jul; 1(1):6-8.
    View in: PubMed
    Score: 0.129
  44. Maximizing the cost-effectiveness of lipid-lowering therapy. Arch Intern Med. 1998 Oct 12; 158(18):1977-89.
    View in: PubMed
    Score: 0.123
  45. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
    View in: PubMed
    Score: 0.117
  46. 2017 Focused Update of the 2016?ACC?Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in?the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017 Oct 03; 70(14):1785-1822.
    View in: PubMed
    Score: 0.114
  47. Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease. Circulation. 2017 05 30; 135(22):2204-2206.
    View in: PubMed
    Score: 0.111
  48. A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. Am J Cardiol. 2017 Aug 15; 120(4):569-576.
    View in: PubMed
    Score: 0.111
  49. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. Atherosclerosis. 2017 06; 261:12-18.
    View in: PubMed
    Score: 0.111
  50. Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes Obes Metab. 2017 01; 19(1):98-107.
    View in: PubMed
    Score: 0.107
  51. Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Am J Cardiol. 1996 Sep 01; 78(5):532-5.
    View in: PubMed
    Score: 0.106
  52. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016 Apr 19; 315(15):1580-90.
    View in: PubMed
    Score: 0.103
  53. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016 07 05; 68(1):92-125.
    View in: PubMed
    Score: 0.103
  54. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. Clin Cardiol. 2016 Mar; 39(3):137-44.
    View in: PubMed
    Score: 0.103
  55. Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. Lipids Health Dis. 2015 Sep 04; 14:103.
    View in: PubMed
    Score: 0.099
  56. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16; 372(16):1500-9.
    View in: PubMed
    Score: 0.096
  57. Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin. Arterioscler Thromb Vasc Biol. 2014 Nov; 34(11):2465-72.
    View in: PubMed
    Score: 0.093
  58. Review of clinical practice guidelines for the management of LDL-related risk. J Am Coll Cardiol. 2014 Jul 15; 64(2):196-206.
    View in: PubMed
    Score: 0.092
  59. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Nov 29; 367(22):2089-99.
    View in: PubMed
    Score: 0.081
  60. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
    View in: PubMed
    Score: 0.080
  61. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J. 2012 Mar; 163(3):515-21, 521.e1-3.
    View in: PubMed
    Score: 0.078
  62. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet. 2011 Oct 29; 378(9802):1547-59.
    View in: PubMed
    Score: 0.075
  63. Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). Curr Med Res Opin. 2011 Jun; 27(6):1119-29.
    View in: PubMed
    Score: 0.073
  64. Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. Cardiovasc Drugs Ther. 2011 Feb; 25(1):59-67.
    View in: PubMed
    Score: 0.072
  65. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord. 2009 Dec; 7(6):601-10.
    View in: PubMed
    Score: 0.066
  66. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009 Dec; 158(6):896-901.e3.
    View in: PubMed
    Score: 0.066
  67. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol. 2009 Jun 15; 103(12):1694-702.
    View in: PubMed
    Score: 0.064
  68. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009 Feb 15; 103(4):515-22.
    View in: PubMed
    Score: 0.062
  69. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol. 2009 Feb 01; 103(3):369-74.
    View in: PubMed
    Score: 0.062
  70. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008 Apr 29; 51(17):1632-41.
    View in: PubMed
    Score: 0.060
  71. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol. 2008 Feb 15; 101(4):490-6.
    View in: PubMed
    Score: 0.058
  72. Hyperlipidemia following heart transplantation: natural history and intervention with mevinolin (lovastatin). Transplant Proc. 1987 Aug; 19(4 Suppl 5):60-2.
    View in: PubMed
    Score: 0.057
  73. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007 Aug; 23(8):2009-26.
    View in: PubMed
    Score: 0.057
  74. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol. 2007 Jun 15; 99(12):1706-1713.
    View in: PubMed
    Score: 0.056
  75. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006 Oct; 22(10):2041-53.
    View in: PubMed
    Score: 0.053
  76. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004 Aug; 58(8):746-55.
    View in: PubMed
    Score: 0.046
  77. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clin Ther. 2003 Jun; 25(6):1670-86.
    View in: PubMed
    Score: 0.042
  78. Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. Am J Cardiol. 2003 May 01; 91(9):1134-6.
    View in: PubMed
    Score: 0.042
  79. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 2003 Jan 01; 91(1):33-41.
    View in: PubMed
    Score: 0.041
  80. Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. J Mol Med (Berl). 2002 11; 80(11):737-44.
    View in: PubMed
    Score: 0.040
  81. Familial hypercholesterolaemia: optimum treatment strategies. Int J Clin Pract Suppl. 2002 Jul; (130):22-6.
    View in: PubMed
    Score: 0.040
  82. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med. 2001 Aug 15; 111(3):185-91.
    View in: PubMed
    Score: 0.037
  83. A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis. 2001 Feb 15; 154(3):633-40.
    View in: PubMed
    Score: 0.036
  84. Development and assessment of antiatherosclerotic therapies beyond low-density lipoprotein cholesterol and blood pressure. Curr Atheroscler Rep. 2000 Jul; 2(4):281-3.
    View in: PubMed
    Score: 0.035
  85. Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. Diabetes Care. 2020 05; 43(5):1077-1084.
    View in: PubMed
    Score: 0.034
  86. A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. J Mol Med (Berl). 2000; 78(10):562-8.
    View in: PubMed
    Score: 0.033
  87. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.
    View in: PubMed
    Score: 0.033
  88. Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. Am Heart J. 2020 03; 221:60-66.
    View in: PubMed
    Score: 0.033
  89. Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study. Atherosclerosis. 1999 Jun; 144(2):435-42.
    View in: PubMed
    Score: 0.032
  90. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol. 1998 Nov 05; 82(9A):3Q-12Q.
    View in: PubMed
    Score: 0.031
  91. Effect of Evolocumab on Coronary?Plaque Composition. J Am Coll Cardiol. 2018 10 23; 72(17):2012-2021.
    View in: PubMed
    Score: 0.031
  92. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. JAMA Cardiol. 2018 02 01; 3(2):164-168.
    View in: PubMed
    Score: 0.029
  93. Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. J Am Heart Assoc. 2017 01 10; 6(1).
    View in: PubMed
    Score: 0.027
  94. Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. J Am Coll Cardiol. 2016 12 06; 68(22):2488-2490.
    View in: PubMed
    Score: 0.027
  95. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Control Clin Trials. 1996 Dec; 17(6):550-83.
    View in: PubMed
    Score: 0.027
  96. On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Am Heart J. 2016 Dec; 182:89-96.
    View in: PubMed
    Score: 0.027
  97. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation. 1996 Apr 01; 93(7):1334-8.
    View in: PubMed
    Score: 0.026
  98. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). Am Heart J. 2016 Jun; 176:83-92.
    View in: PubMed
    Score: 0.026
  99. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. J Clin Lipidol. 2013 Jul-Aug; 7(4):292-303.
    View in: PubMed
    Score: 0.021
  100. Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care. J Clin Lipidol. 2012 Nov-Dec; 6(6):545-52.
    View in: PubMed
    Score: 0.020
  101. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011 Dec 01; 365(22):2078-87.
    View in: PubMed
    Score: 0.019
  102. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J Clin Lipidol. 2011 Nov-Dec; 5(6):474-82.
    View in: PubMed
    Score: 0.018
  103. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 May-Jun; 5(3):133-140.
    View in: PubMed
    Score: 0.018
  104. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol. 2005 May 17; 45(10):1611-9.
    View in: PubMed
    Score: 0.012
  105. Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging. Magn Reson Imaging. 2004 Nov; 22(9):1249-58.
    View in: PubMed
    Score: 0.012
  106. Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. Circ Res. 2001 May 11; 88(9):969-73.
    View in: PubMed
    Score: 0.009
  107. A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ Res. 2000 Mar 03; 86(4):391-5.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.